Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.

You may also be interested in...



Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure

Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.

Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure

Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.

Biovest Ends Therapeutic Cancer Vaccine Trial Early On Positive DMC Signal

Firm seeks “accelerated or conditional” approval path from FDA.

Related Content

Topics

UsernamePublicRestriction

Register

OM017315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel